Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2013. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the company's issued share capital as of August 30, 2013:
- Total Issued Ordinary Shares: 5,413,579,513 (25p each)
- Treasury Shares: 514,835,412
- Total Voting Rights: 4,898,744,101
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,898,744,101) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (514,835,412) to calculate the effective float.
- Review the company's Form 20-F for comprehensive financial performance data not included in this 6-K.